Tower Research Capital (TRC)’s Applied Therapeutics APLT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-19,675
Closed -$1.97K 5108
2025
Q4
$1.97K Sell
19,675
-14,680
-43% -$9.33K ﹤0.01% 4606
2025
Q3
$20.8K Sell
34,355
-1,868
-5% -$880 ﹤0.01% 3277
2025
Q2
$11.3K Buy
36,223
+16,768
+86% +$6.49K ﹤0.01% 3918
2025
Q1
$9.51K Sell
19,455
-4,970
-20% -$2.93K ﹤0.01% 3765
2024
Q4
$20.9K Buy
24,425
+23,893
+4,491% +$150K ﹤0.01% 3152
2024
Q3
$4.52K Buy
+532
New +$3.13K ﹤0.01% 4515
2024
Q2
Sell
-10,261
Closed -$69.8K 5669
2024
Q1
$69.8K Sell
10,261
-12,914
-56% -$58K ﹤0.01% 2056
2023
Q4
$77.6K Sell
23,175
-12,268
-35% -$30.5K ﹤0.01% 2832
2023
Q3
$88.3K Buy
35,443
+27,963
+374% +$46.1K ﹤0.01% 2073
2023
Q2
$9.57K Buy
7,480
+672
+10% +$891 ﹤0.01% 4253
2023
Q1
$6K Buy
6,808
+1,730
+34% +$1.7K ﹤0.01% 4819
2022
Q4
$4K Sell
5,078
-5,368
-51% -$4.25K ﹤0.01% 4970
2022
Q3
$10K Sell
10,446
-215
-2% -$258 ﹤0.01% 4508
2022
Q2
$10K Buy
10,661
+4,799
+82% +$7.86K ﹤0.01% 4424
2022
Q1
$13K Buy
5,862
+1,593
+37% +$4.27K ﹤0.01% 3953
2021
Q4
$38K Buy
4,269
+3,157
+284% +$41.5K ﹤0.01% 2993
2021
Q3
$18K Sell
1,112
-345
-24% -$5.96K ﹤0.01% 3799
2021
Q2
$31K Sell
1,457
-302
-17% -$5.72K ﹤0.01% 3442
2021
Q1
$33K Buy
1,759
+23
+1% +$496 ﹤0.01% 3477
2020
Q4
$38K Sell
1,736
-11,414
-87% -$238K ﹤0.01% 3363
2020
Q3
$273K Buy
13,150
+10,442
+386% +$271K ﹤0.01% 2263
2020
Q2
$98K Buy
+2,708
New +$113K ﹤0.01% 2471
2020
Q1
Sell
-792
Closed -$22K 3006
2019
Q4
$22K Buy
+792
New +$13.6K ﹤0.01% 1848
2019
Q3
Sell
-494
Closed -$4K 4057
2019
Q2
$4K Buy
+494
New +$4.68K ﹤0.01% 3003

Tower Research Capital (TRC)'s APLT Position: Q1 2026 in Review

Tower Research Capital (TRC) sold out of Applied Therapeutics (APLT) in Q1 2026, closing a stake of 19,675 shares — an estimated $1.97K sold.

Tower Research Capital (TRC) first reported a position in APLT in Q2 2019 and held it in 24 quarters. The position peaked at $273K in Q3 2020. 0 funds tracked by Wall St. Rank hold APLT as of Q1 2026.

  • Tower Research Capital (TRC) reported no remaining Applied Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Tower Research Capital (TRC) sold 19,675 Applied Therapeutics shares in Q1 2026, an estimated $1.97K.
  • Tower Research Capital (TRC) first reported a position in Applied Therapeutics in Q2 2019 and held it in 24 quarters.
  • Tower Research Capital (TRC)'s Applied Therapeutics position peaked at $273K in Q3 2020.
  • 0 funds tracked by Wall St. Rank held Applied Therapeutics as of Q1 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2026, filed 15 May 2026.